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Abstract 
 
Objective(s) 
Psychotropic medications produce their effects, in part, through increasing neurotrophin levels in the brain. 
Since studies concerning nerve growth factor (NGF) analysis have been limited in scope, in the current 
experiments we investigated the effects of diverse psychotropic agents on NGF protein levels in various 
brain regions of rat.  
Materials and Methods 
Male Wistar rats received acute and chronic administration of drugs and electroconvulsive shock (ECS).          
Twenty four hr after the last treatment, NGF quantification was performed using sandwich ELISA kit.  
Results 
Acute administration of desipramine, phenelzine, fluoxetin, chlordiazepoxide (10 mg/kg, each), haloperidol 
(1 mg/kg), or clozapine (20 mg/kg) failed to alter NGF protein in any brain structure investigated. However, 
a single ECS treatment significantly elevated NGF protein in the hippocampus. Chronic administration           
(21 days) of desipramine, fluoxetine, phenelzine, haloperidol and clozapine led to a reliable enhancement of 
NGF protein in the frontal cortex. In addition desipramine, fluoxetine, phenelzine, and clozapine 
significantly increased NGF protein in the hippocampus. In the olfactory bulb, chronic injections of 
desipramine and fluoxetine elevated NGF level, however, phenelzine and haloperidol decreased NGF. 
Repeated applications of ECS (10 days) led to a remarkable augmentation of NGF protein in the frontal 
cortex, hippocampus, amygdala, and olfactory bulb. Neither acute nor chronic treatment with the 
benzodiazepine chlordiazepoxide altered NGF level in the examined brain regions. 
Conclusion 
These findings suggest that diverse psychotropic treatments may regulate NGF protein level in a brain 
region-specific fashion which may be indicative of their therapeutic properties. 
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Introduction                                                                                                                              
The effects of psychotropic treatments on the 
norepinephrine (NE) and serotonin (5-HT) 
neurotransmitter systems in the brain are well 
known (1). Since the therapeutic actions of 
these agents are dependent on chronic 
treatment, increased levels of NE or 5-HT 
alone cannot account for their efficacy. Hence, 
alternative possibilities such as slow adaptive 
processes and intracellular signal transduction 
targets may be considered in this regard (2, 3). 
Over the past decade; increased neurogenesis, 
neuroplasticity and neuroprotection have 
become the focus of intense research 
especially in neuropsychiatric disorders 
associated with progressive brain tissue loss 
such as schizophrenia, bipolar disorder, and 
major depression (4, 5). In parallel, an interest 
in neurotrophins including NGF, brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 
(NT-3) and their capacities to regulate central 
neurotransmission and promotion of 
neuroplasticity has been grown (6-8). There is 
ample evidence that neurotrophins exert 
numerous neuroprotective effects under 
pathological conditions which might be 
important in particular for neurodegenerative 
and psychiatric diseases (9). In a study 
conducted by Manev et al, antidepressant 
drugs improved information processing within 
neuronal networks through their neurotrophic 
effects (10). Accumulating preclinical and 
clinical data indicate that dysfunctions of NGF 
and BDNF may contribute to synaptic 
dysconnectivity and impaired brain 
development which lead to the schizophrenic 
syndrome or at least some of its presentations 
(11, 12). In rat brain associated with 
depression, atrophy was shown in several 
brain regions such as hippocampus, frontal 
cortex, and amygdala which was paralleled 
with the reduction of neurotrophic factor 
expression including NGF (13). It is also 
reported that NGF has profound effects on the 
growth, remodeling, synaptogenesis, and 
stability of dendrites and axons in 
hippocampal and cortical neurons (14). In 
general, the neurotrophic hypothesis of 
depression proposes that the etiology of 
depression and the action of antidepressant 
drugs are due, in part, to the regulation of 
central neurotrophin signaling. This has led to 
the investigation of the effects of different 
classes of antidepressants on the protein levels 
of neurotrophins in rat brain regions (15, 16). 
Vinay et al., have reported the different effects 
of typical and atypical antipsychotics on NGF 
expression in the cortex and nucleus basalis of 
rat (13). In addition, chronic ECS, an effective 
somatic treatment against drug-resistant 
depression, has been shown to increase NGF 
protein in the rhinal cortex and hippocampus 
(17-19). However, as compared to the 
regulation of BDNF levels which is most 
commonly studied, much less work has been 
done to analyze NGF protein level in different 
brain regions following administration of 
diverse psychotropic agents. Thus, the present 
study was designed to investigate the effects of 
acute and chronic treatments with different 
pharmacologic and somatic antidepressants on 
NGF protein levels in multiple brain regions of 
rat. To determine whether the regulation of 
NGF was unique to antidepressant treatments, 
antipsychotic and anxiolytic drugs were also 
considered. 
 
Materials and Methods  
Animals 
Male Wistar rats weighing 250–300 g from 
our own animal facilities were used in this 
study. The animals were housed in pairs in 
polycarbonate cages and maintained on a 12 hr 
light/dark cycle in a temperature and humidity-
controlled colony (22 °C). The animals were 
given free access to food pellets and water. 
The experimental procedures were conformed 
to the provisions of the Declaration of Helsinki 
and were also approved by the local Ethics 
Committee of AJA University of Medical 
Sciences. 
 
Drug treatments  
Dose and duration of drug treatment was 
selected based on the previous studies showing 
the  elevation  of  BDNF  or  NGF  mRNA        
(12, 13). Rats received once-daily 
subcutaneous injection of sterile saline (0.9%) 
or drug for either 1 day (n = 7 per group) or 
21  days (n  =  7). Drugs were dissolved in  
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sterile water and given in appropriate doses as 
follows: the tricyclic antidepressant (TCA); 
desipramine HCl (Sigma, St. Louis MO; 
10  mg/kg), the selective serotonin reuptake 
inhibitor (SSRI); fluoxetine HCl (Anawa, 
Switzerland; 10  mg/kg), the monoamine 
oxidase inhibitor (MAOI); phenelzine sulfate 
(Sigma, St. Louis MO; 10  mg/kg), the 
benzodiazepine; chlordiazepoxide HCl 
(Sigma, St. Louis MO; 10  mg/kg), and the 
typical antipsychotic; haloperidol HCl (Tocris, 
Ellisville MO; 1  mg/kg). In addition, the 
atypical antipsychotic; clozapine (Tocris, 
Ellisville MO; 20 mg/kg) was dissolved in a 
small volume of acetic acid, adjusted to pH 5.2 
with 10  N NaOH and brought up to final 
volume with sterile water. Control animals 
received only the vehicle (n=7).                                                                                                                             
 
Electroconvulsive shock                                                                                    
Rats were administered sham or ECS 
treatment either for 1 day (n = 7 per group) or 
10  days (n  =  7). To administer the ECS, the 
animal was lightly restrained by being 
wrapped in a paper towel with its head 
exposed. Conducting jelly was applied to the 
ears and electric current was administered 
between two earclip electrodes (50  mA, 
0.5 Sec) using an electroshock generator (Ugo 
Basile, Italy). Sham-stimulated animals 
received the same treatment, except that no 
current was administered. This level and 
duration of shock produces a seizure that lasts 
less than 1  min and is characterized by full 
extension of the hind limbs (tonic phase) for 
10-15  Sec, followed by repetitive flexion-
extension of the forelimbs for 10-15  Sec 
(clonic phase). After the cessation of the 
shock, each rat was placed in a plastic cage 
where remained singly housed for 1  hr and 
returned to its home cage afterwards. 
 
NGF quantification  
Twenty-four hours after the last psychotropic 
treatment, rats were decapitated and their 
brains were quickly removed from the skull 
for dissection into the following regions: 
frontal cortex, hippocampus, amygdala, 
olfactory bulb, and brain stem. NGF protein 
levels were quantified using a commercially 
available sandwich enzyme-linked 
immunosorbent assay (ELISA) kit according 
to the manufacturer's instructions (Millipore, 
Billerica, MA). Briefly, each brain region was 
homogenized (1:10, w/v) in phosphate buffer 
solution (PBS) with 1 mM 
phenylmethylsulfonyl fluoride (PMSF)  and        
1 mM ethylene glycol bis(2-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA). Microtiter 
plates (96-well flat-bottom) were coated for       
24 hr with the samples diluted 1:2 in sample 
diluent. Then, plates were washed four times 
with sample diluents. Monoclonal anti-NGF 
rabbit antibody diluted 1:1000 in sample 
diluent was incubated for 3 hr at room 
temperature. After washing, a second 
incubation with peroxidase-conjugated anti-
rabbit antibody diluted 1:1000 was carried out 
for 1 hr at room temperature. After addition of 
streptavidin enzyme, substrate and stop 
solution, the amount of NGF was determined 
for absorbance in 450 nm. A standard curve, 
demonstrating a direct relationship between 
optical density and NGF concentration was 
considered which ranged from 7.8 to 500 pg of 
NGF. Total NGF protein was measured by 
Lowry's method using bovine serum albumin 
as a standard (20). 
 
Statistical analysis 
Data were analyzed by one-way analysis of 
variance (ANOVA) followed by the Tukey’s 
test. Data are presented as mean±SEM. The 
level of significance was set at P<0.05. 
 
Results 
Effects of the psychotropic drugs on NGF 
protein levels     
Acute administration of the drugs failed to 
change NGF protein levels in the examined 
brain regions (Figure 1, P>0.05). However, 
three weeks administration of desipramine, 
fluoxetine, phenelzine, haloperidol, and 
clozapine led to a significant enhancement of 
NGF protein in the frontal cortex (Figure 2, 
P<0.05,  P<0.05,  P<0.001,  P<0.05,  P<0.01, 
respectively). In addition; desipramine, 
fluoxetine, phenelzine, and clozapine 
increased NGF protein in the hippocampus 
(Figure 2, P<0.01,  P<0.05,  P<0.05,  P<0.001,  
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respectively). In the olfactory bulb; desipramine 
and fluoxetine elevated NGF protein level 
(Figure 2, P<0.05, P<0.01, respectively), while, 
phenelzine and haloperidol caused a significant 
decrease of this neurotrophine (Figure 2, P<0.05, 
P<0.05, respectively). All drugs were unable to 
demonstrate significant change in the amygdala 
and brain stem as compared to the controls 
(Figure 2, P>0.05). Neither acute nor chronic 
treatment with the benzodiazepine 
chlordiazepoxide altered NGF levels in the 
selected brain regions (Figures 1 and 2, P>0.05). 
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Figure 1. Effect of acute administration of psychotropic 
drugs on NGF protein level: Single injection of the 
drugs failed to alter NGF level in the brain regions 
investigated significantly, as compared to the control 
(P>0.05). Data are presented as mean±SEM.   
Data obtained from clozapine vehicle group was similar 
to that of other drugs, thus, all were integrated. 
pg/µl: picogram/microliter 
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Figure 2. Effect of chronic administration of psychotropic 
drugs on NGF protein level: The drugs being able to 
regulate NGF protein level are shown. According to the 
ANOVA/Tukey test, all of the drugs were unable to 
demonstrate statistically significant change in the 
amygdala and brain stem as compared to the controls 
(P>0.05). Chronic treatment with the benzodiazepine 
chlordiazepoxide did not alter NGF levels in the selected 
brain regions. Data are presented as mean±SEM.   
* P<0.05, 
# P<0.01, *** P<0.001 vs. control. 
Effect of ECS on NGF protein levels                                     
A single ECS treatment was sufficient to cause 
a significant increase of NGF protein in the 
hippocampus (Figure 3, P<0.05). Repeated 
applications of ECS resulted in a remarkable 
augmentation of NGF level in the frontal 
cortex, hippocampus, amygdala, and olfactory 
bulb (Figure 4, P<0.001,  P<0.001,  P<0.01, 
P<0.01, respectively). 
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Figure 3. Effect of acute treatment with ECS on NGF 
protein level: A single ECS treatment led to a 
significant increase of NGF protein in the hippocampus, 
as compared to the sham-stimulated (control) animals. 
Data are presented as mean±SEM. 
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Figure 4.  Effect of chronic treatment with ECS on NGF 
protein level: Ten days of ECS treatments, except for 
the brain stem, resulted to a significant augmentation of 
NGF in other brain structures examined, as compared to 
the sham-stimulated (control) animals. Data are 
presented as mean±SEM. 
** P< 0.01, *** P< 0.001 
 
Discussion    
Over the recent years, after the previously 
dominating interest in the effects of 
psychotropic treatments on neurotransmitter 
levels in the brain, the focus of research has 
shifted towards the effects of these agents on 
intraneuronal signal transduction and cellular  
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resilience (2, 3).  The  discovery  indicating        
that the psychotropic medications are 
neuroprotective and induce neurogenesis, has 
opened a new line of research in exploring the 
causes and treatments of neuropsychiatric 
diseases. Implication of neurotrophins in the 
mode of action of antidepressant drugs has 
been previously reported and is considered as 
an exciting new mechanism of action of these 
drugs (9, 12). Antidepressants have been 
shown to modulate growth factors even in 
cultured cells (10). In the present study, the 
effects of acute and chronic administration of 
different psychotropic agents on NGF protein 
levels in multiple brain regions of rat were 
investigated. According to the results, chronic 
treatment with pharmacologically distinct 
antidepressant drugs including desipramine, 
fluoxetine, and phenelzine significantly 
increased NGF protein levels in the frontal 
cortex (Figure 2). Frontal cortex is likely to be 
involved in depression and is sensitive to the 
effects of anti-stress and anti-depressant 
treatments (21). In postmortem studies of 
depressed patients, cellular and morphological 
changes including reductions in the number of 
glia and neuronal size of cortical structures 
have been observed (22). Similar changes have 
been reversed by chronic fluoxetine treatment 
in the cerebral cortex of rodents (23). As 
shown in Figure 2, chronic treatment with 
phenelzine induced elevation of NGF protein 
in the frontal cortex to a greater extent than 
either desipramine or fluoxetine. It is possible 
that phenelzine which inhibits the metabolism 
of all monoamines, might have greater effects 
on NGF protein levels than drugs which are 
more selective for specific monoamines. 
Previously, chronic administration of 
tranylcypramine; another MAOI, has been 
shown to increase NGF protein level in the 
frontal cortex (24). In the hippocampus, the 
aforementioned antidepressant drugs increased 
NGF (Figure 2). It is also known that, NGF 
regulates adult hippocampal neurogenesis (4). 
It is reported that hippocampal neurogenesis is 
one of those plastic processes that are 
regulated bi-directionally in response to either 
stress or antidepressant treatment (25-27). 
Meanwhile, phenelzine, in contrast to 
desipramine or fluoxetine, significantly 
reduced NGF level in the olfactory bulb 
(Figure 2). It appears that the regulation of 
NGF signaling, either positive or negative, 
could be involved in causing adaptive changes 
in neural plasticity induced by antidepressants.  
As shown in Figures 1 and 2, neither acute 
nor chronic treatment with the anxiolytic 
chlordiazepoxide altered NGF level in any 
brain region investigated. Although anxiety 
can be effectively treated with SSRI 
antidepressants such as fluoxetine, the 
converse usually does not hold true. According 
to clinical data, patients with depression are 
generally not treated effectively with most 
benzodiazepine anxiolytics. Our data suggest 
that the inability of benzodiazepines to treat 
depression may, in part, be due to their 
inability to regulate central NGF levels. 
Three weeks administration of the 
antipsychotics (haloperidol or clozapine), 
elevated NGF protein level in the frontal 
cortex (Figure 2). This, according to the 
sensitivity of the frontal cortex to the effects of 
antidepressant treatments (21), may be related 
to the efficacy of haloperidol or clozapine in 
treating depression. It is worth mention that 
antipsychotics have been recommended for the 
treatment of psychosis associated with 
depression (15). Meanwhile, the ability of 
antipsychotics to regulate central NGF levels 
has not been extensively investigated. Over the 
years, antidepressant treatments have been 
combined with antipsychotic drugs to treat 
bipolar and treatment-resistant depressions 
(28, 29). This may be due to the potential 
synergistic effects of both drug regimens on 
NGF protein levels. As shown in Figure 2, 
repeated injections of clozapine led to a 
remarkable augmentation of NGF protein in 
the hippocampus. It is reported that 
hippocampal dysfunction and/or atrophy are 
implicated in major neuropsychiatric disorders 
such as schizophrenia and mood disorders (4); 
therefore, clozapine via enhancement of the 
hippocampal NGF may increase neural 
proliferation and, perhaps, promote subsequent 
survival of neurons in the hippocampus, 
leading to the improvement of hippocampal 
function. This latter finding may justify the 
hippocampal neurogenesis or neuroprotection  
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induced by atypical antipsychotics (16, 28). 
However, the extent to which atypical 
antipsychotics including clozapine can 
modulate cell division or survival of newly 
generated cells within the hippocampus 
remains to be established. In a study conducted 
by Halim et al,  administration of clozapine, 
10 mg/kg for 28 days elevated NGF mRNA in 
sub-regions of the hippocampus (30). It is also 
well known that 
 NGF enhances cholinergic functioning and 
plays an important role in cognitive function 
(9). Meanwhile, the lack of effect of chronic 
treatment with antipsychotics on BNDF or 
NGF levels in the hippocampus has been 
reported by Valvassori et al (31). The 
discrepancy between our findings and those of 
Valvassori et al could be due to the differences 
in the duration of treatment, route of drug 
administration, and dosing regimen.   
As shown in Figure 2, haloperidol had no 
appreciable effect on NGF protein levels in the 
hippocampus, as compared to clozapine. Thus, 
it seems that hippocampal neurogenesis is not 
affected by this typical antipsychotic. Several 
studies have indicated that haloperidol not 
only fails to stimulate neurogenesis in rats, but 
also appears to be neurotoxic by inducing 
apoptotic cell death that may be in part due to 
the decline of neurotrophins (32). In addition, 
chronic treatment with haloperidol decreased 
NGF protein level in the olfactory bulb (Figure 
2). As previously shown, haloperidol produces 
mixed effects on NGF mRNA levels; either 
reduction in various hippocampal subfields 
with 1 mg/kg given for 28 days, or no change 
after 2 mg/kg given for 21 days (13, 16). At 
protein level, administration of haloperidol for 
29 days reduced NGF in the hippocampus and 
frontal cortex (33). In general,  it  appears           
that second-generation antipsychotics in 
comparison with the first-generation drugs 
induce less deleterious effects on the levels of 
neurotrophic factors and cognitive function.  
ECS, an effective somatic treatment against 
drug-resistant  depression,  was  sufficient          
to cause a significant elevation of NGF protein 
level  in  the  hippocampus  following             
single administration (Figure 3), while, acute 
administration of pharmacological 
antidepressants did not alter NGF protein level 
in any brain structure investigated (Figure 1). 
Chronic application of ECS caused a more 
widespread up-regulation of NGF levels than 
the  pharmacologic  treatments  (Figure  4).             
It appears that seizures evoked by ECS 
increase trophic factor expression which may 
serve  as  a  neuroprotective  function.  This         
may  be  in  parallel  with  the  previous           
reports indicating that somatic antidepressant 
treatments including ECS, increase 
hippocampal neurogenesis and protect against 
apoptotic neuronal cell death via sustained 
enhancement of fibroblast growth factor-2 
(FGF-2) and NGF mRNA (18). Over the 
years, various theories concerning the 
mechanism  of  action  of  ECS  have              
been proposed including psychological, 
neurophysiological, neurochemical, 
neuroendocrine, and neuropeptide 
mechanisms. However, there is no single 
theory that satisfactorily explains the 
mechanism of ECS in various psychiatric 
illnesses. According to our data, it seems that 
the efficiency of ECS in drug-resistant 
depression might, in part, be linked to its 
regulatory effect on NGF protein levels in the 
brain. 
 
Conclusion 
The present work provide evidence that 
diverse pharmacologic and somatic 
antidepressant treatments, as well as 
antipsychotics, increase NGF protein level in a 
brain-region specific manner, even though 
they have different mechanisms of action at 
neurotransmitter systems. 
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